Trial finds drug reteplase may be another option for stroke thrombolysis
UC expert comments on study to TCT MD
The University of Cincinnati's Pooja Khatri commented to TCTMD on the RAISE trial that found drug reteplase may be a safe and effective option to treat acute ischemic stroke.
Like drugs tenecteplase and alteplase, reteplase is a clot-busting medication that was administered to patients within 4.5 hours of stroke onset during the trial. The drug was found to lead to a higher rate of excellent functional outcome compared with standard alteplase with no significant increase in symptomatic intracranial hemorrhage, other bleeding outcomes or death.
The trial “raises the possibility of another intravenous thrombolytic drug that we could use to treat acute stroke patients,” said Khatri, MD, professor, vice chair of research and division chief in the Department of Neurology & Rehabilitation Medicine at UC's College of Medicine and associate director of the UC Gardner Neuroscience Institute, noting that this is the first phase III trial to address the topic.
“It opens some doors, but we need more data to know if this is going to have a role in our armamentarium as part of our standard of care in the long run,” Khatri added.
Featured photo at top of illustration of brain with stroke symptoms. Photo/PeterSchreiber.media/iStock.
Related Stories
CureToday: UC enrolling patients for glioblastoma trial
March 29, 2022
CureToday highlighted the University of Cincinnati's new glioblastoma immunotherapy trial in a recent article.
55KRC: UC researchers examine role of stress in Parkinson's disease
March 8, 2022
University of Cincinnati researchers Kim Seroogy, Teresa Reyes and James Herman were featured on 55KRC's Simply Medicine program to discuss their research into the role of stress in Parkinson's disease.
Five to Thrive Live features UC's Sengupta
October 14, 2022
The University of Cincinnati's Soma Sengupta, MD, PhD, joined the Five to Thrive Live podcast to discuss "Humanizing Brain Tumors."